A new diagnostic paradigm for cancer patients is required to enable the success of rapidly evolving arsenal of targeted therapies.
It is increasingly challenging for physicians to incorporate the latest molecular diagnostic tests to help guide treatment of cancer patients due to the growing number of molecular subtypes that are understood across tumor types.
As more targeted therapies are approved for new molecular subtypes, the number of tests that need to be performed on each patient to determine their subtype increases and very quickly exhausts the very small amount of tumor tissue that is available in routine, clinical samples.
Importantly, as patients’ molecular subtypes are more broadly incorporated into physician treatment decisions, we continue to further our understanding of a pathway view of cancer. Patients with different tumor types can have same molecular subtype – often, these therapies are applicable across tumor types since they are targeting the same pathway.
Foundation Medicine is committed to addressing these challenges by developing and applying the most advanced scientific methods to bring comprehensive cancer genome analysis to routine cancer care. The company’s initial clinical assay, FoundationOneTM, is a fully informative genomic profile to identify a patient’s individual molecular alterations and match them with relevant targeted therapies and clinical trials.
We invite you to explore Foundation Medicine’s recent Posters and Abstracts and Scientific Publications that highlight the progress Foundation Medicine is making in developing cancer diagnostic tests that will address the many challenges in this evolving landscape.